FZD7 and neoplasm: A series of studies in vitro and in vivo indicated that SHH002-hu1 could effectively target Fzd7+ cells (Fig. 2a-c) and Fzd7+ TNBC tumor tissue (Fig. 2d, e), and inhibit TNBC via blocking Wnt/β-catenin signaling pathway (Fig. 3d-f).